Project Grant R21CA299361
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $471K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98105, USA
Similar Awards
- This federal Project Grant award of $456,414 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support the development and clinical evaluation of B7-H3 chimeric antigen receptor (CAR) T cells for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults. The grant, awarded to Seattle Children's Research Institute, will fund a Phase 2 clinical trial to assess the efficacy and safety of repeatedly administering the B7-H3 CAR T cells...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- This $177,180 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Fred Hutchinson Cancer Center in Seattle, Washington supports research to improve engineered TCR-T cell therapy for solid tumors. The key goals are to investigate whether engineered TCR-T cells form PD-1+TCF1+ stem-like progenitor exhausted T cell populations in tumor-draining lymph nodes, similar to endogenous tumor-specific T cells. This could impact the long-term persistence...
- The National Cancer Institute (NCI) awarded a $177,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The funding supports research to investigate the role of the NLRC4 inflammasome and caspase-8 activation in the pathogenesis of fibrolamellar carcinoma (FLC), a rare and aggressive form of liver cancer. The researchers will use mouse liver organoids engineered with the DNAJB1-PRKACA...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This Project Grant award from the National Institutes of Health's (NIH) National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $901,205 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct genome-wide studies examining how tumor immune editing in early-stage cancers leads to immune evasion and suppression. The research aims to identify key genes, pathways, and processes that are epigenetically repressed during early tumor...
- This Project Grant award of $402,400.00, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to explore myeloid-derived suppressor cells (MDSCs) as a therapeutic target for the treatment of hepatoblastoma (HB), a rare childhood liver cancer. The key goals are to determine which oncogenes drive the recruitment of PMN-MDSCs to HB tumors, and to test the effects of a CXCR2 inhibitor (SB225002) on HB tumor growth, both as a...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $434,361.00 to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a multispecific T cell engaging therapy for the treatment of mixed phenotype acute leukemia (MPAL). MPAL is a high-risk leukemia subtype that presents with both myeloid (e.g. CD33) and lymphoid (e.g. CD19) surface antigens, resulting in lower cure rates compared to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...